Mode
Text Size
Log in / Sign up
Phase 4 Completed N=236 Randomized Double-blind Treatment

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

Source: ClinicalTrials.gov NCT00798759 ↗
Enrolled (actual)
236
Serious AEs
1.3%
Results posted
Apr 2012
Primary outcomePrimary: Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT) — 0.7; 0.6 Seconds

Summary

The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)
0.7; 0.6
SECONDARY
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
-1.9; 0.6

Eligibility Criteria

Inclusion Criteria

  • 18 years or older.
  • Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.
  • Intraocular pressure (IOP) controlled with BAK (benzalkonium chloride) preserved IOP-lowering medication for 1 year, with last 6 months on XALATAN® monotherapy.
  • Best corrected visual acuity of -0.6 logMAR or better in each eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Treatment with BAK preserved artificial tears within 30 days of Visit 1.
  • Known or suspected Sjogren's disease.
  • Uncontrolled IOP.
  • History or evidence of infectious or inflammatory ocular conditions.
  • Progressive retinal or optic nerve disease.
  • Ocular laser surgery within 3 months of Visit 1.
  • Keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface within 1 year of Visit 1.
  • Current use of punctal plugs or punctal cautery.
  • Use of systemic medications that has not been stable for 30 days prior to Visit 1.
  • Use of contact lens within 30 days of Visit 1.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00798759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search